Let's talk about the IL-23 pathway in PsA
Agenda
Learning objectives
After this meeting, participants should be able to:
- Describe the different phenotypes of psoriatic arthritis and how they relate to comorbidities and disease progression
- Relate the pathobiology of psoriatic arthritis to the potential efficacy of new treatment options in the current treatment landscape of the disease
- Discuss the recent clinical and mechanistic data on targeting the IL-23 pathway in psoriatic disease and consider the impact of these data on clinical practice
Programme
- 20:00–20:05 Welcome
Dennis McGonagle and Carlo Selmi - 20:05–20:20 Curbside consultation: between bench and bedside
Dennis McGonagle and Carlo Selmi - 20:20–20:55 Interactive panel discussion and Q&A
Moderated by William Tillett - 20:55–21:00 Conclusion and close of meeting
Dennis McGonagle and Carlo Selmi